PMN Stock Analysis: Buy, Sell, or Hold?
PMN - ProMIS Neurosciences Inc. Common Shares (ON)
$13.35
-0.10 (-0.74%)
▼
5d:
+30.24%
30d:
+31.53%
90d:
+2.69%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PMN is 14.3% above its trading range ($11.68). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PMN is 14.3% above its trading range ($11.68). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PMN is currently trading at $13.35, which is considered extended relative to its 30-day fair value range of $9.57 to $11.68.
Technical Outlook: Technically, PMN is in a downtrend. The price is approaching resistance at $11.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PMN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.68 (+159.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PMN is in a downtrend. The price is approaching resistance at $11.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PMN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.68 (+159.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.57 -
$11.68
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+14.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 159.8% below Wall St target ($34.68)
Trading Range Analysis
30-Day Trading Range
$9.57 -
$11.68
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.09
Resistance Level
$11.37
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.70
Wall Street Target
$34.68
(+159.8%)
Share & Embed Analysis
Last updated: July 05, 2026 10:14 AM ET
Data refreshes hourly during market hours. Next update: 11:13 AM
Data refreshes hourly during market hours. Next update: 11:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PMN showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Patrick D Kirwin
BUY
4000 shares
2026-04-22
Eugene Williams
BUY
2000 shares
2026-03-04
Eugene Williams
BUY
1000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
